ArticleMedical journal, Armed Forces India2024
Treating adult patients of severe psoriasis with methotrexate leads to reduction in biomarkers of atherosclerosis: A prospective study.
Article in Medical journal, Armed Forces India, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Methotrexate Exposure and Inflammatory-Metabolic Biomarker Networks in Hospitalized Patients with Psoriasis: A Network Analysis Approach.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The Dynamics of Blood-Count-Derived Inflammatory Indices in the Course of Systemic Treatment for Psoriasis: A Single Center Study.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is a common skin disorder; affecting 0.4-2% of general population and is associated with increased risk of cardiovascular diseases. We conducted this prospective study to determine change in biomarkers of atherosclerosis in plaque psoriasis in patients treated with methotrexate. Methods: The study was carried out at a tertiary care centre over a period of 1 year after institutional ethical clearance. The study included 50 patients. Adults with severe psoriasis not receiving any systemic treatment for last 3 months were included in the study. Clinical parameters including psoriasis area and severity index (PASI), dermatology quality of life index (DLQI) and estimation of IL-6, hsCRP, and HDL levels and LDL: HDL ratio were done at baseline and at 12 weeks. Results: A total of 50 patients were included and 42 completed the study. The mean age and mean duration of disease was 44.4 (±13.2) years and 10.8 (±9.9) years, respectively. Pre- and post-treatment mean PASI was 16.3 (±8.3) and 7.43 (±4.9), respectively ( Conclusion: Methotrexate use in patients with chronic plaque psoriasis reduces the level of biomarkers of atherosclerosis at 12 weeks. Early treatment with methotrexate may help in reduction of cardiovascular risk in psoriasis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.